Data Readouts At The AAIC (Jul 26 - 30): CYCN, SAVA, ALEC...

pharma 022718 25jul21 lt

The Alzheimer's Association International Conference, or AAIC, is the world's largest and most powerful gathering dedicated to dementia research. Every year, the AAIC brings together the world's leading basic science and clinical researchers, next-generation investigators, clinicians, and the care research community to share research findings that will lead to new methods of prevention and treatment, as well as improvements in Alzheimer's disease diagnosis.

This year's conference is scheduled to be held from Jul 26 - 30, 2021, Denver, USA and online.

The following are some of the companies that will be making presentations at the AAIC.

1. Cyclerion Therapeutics Inc. (CYCN)

Cyclerion Therapeutics is scheduled to make a presentation at the upcoming Alzheimer's Association International Conference on July 26.

The company will be presenting the clinical trial design for a phase IIa study of its lead development candidate, CY6463, in participants with Alzheimer's disease with vascular pathology. In addition, research highlighting the potential of neuropsychological biomarkers to guide the clinical development of the company's investigational therapeutics will be presented at the conference.

A 29-day open label phase IIa pilot study of CY6463 in patients with MELAS syndrome is underway, with data expected by year-end 2021. (MELAS - Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes).

CYCN closed Friday's trading at $4.13, up 14.72%.

2. Cassava Sciences Inc. (SAVA)

Cassava Sciences will be presenting new clinical data for SavaDx, an investigational biomarker/diagnostic to detect Alzheimer's disease with a simple blood test, on July 26.

A phase 2b study that evaluated SavaDx for its ability to detect treatment effects of Simufilam versus placebo in a randomized, controlled study completed was completed in 2020.

Simufilam is Cassava Sciences' lead drug candidate to treat Alzheimer's disease.
SAVA closed Friday's trading at $123.38, down 2.55%.

3. Annovis Bio Inc. (ANVS)

Annovis Bio will be presenting new data from phase IIa trial evaluating ANVS401 (posiphen) in patients with Alzheimer's disease and early Parkinson's disease on July 28.

According to the phase IIa data, reported in May of this year, the Alzheimer's disease patients treated with ANVS401 for 25 days showed a statistically significant 30% cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) and Parkinson's disease patients treated with ANVS401 showed a statistically significant 18% motor function improvement as measured by the MDS-UPDRS.

The new data that is going to be presented includes Neurotoxic protein levels, Marker of axonal damage, Inflammatory markers and Efficacy.

ANVS closed Friday's (Jul.23, 2021) trading at $119.00, up 11.10%.

4. Alector Inc (ALEC)

Alector plans to present updated six- and twelve-month data from its phase II trial of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia, dubbed INFRONT-2, on July 29.

Frontotemporal dementia (FTD), a common cause of dementia, is a group of disorders that occur when nerve cells in the frontal and temporal lobes of the brain are lost, causing the lobes to shrink. This results in progressive personality/behavior changes, and impairment of language functions.

The most common genetic causes of FTD are mutations in 'microtubule-associated protein tau' (MAPT), 'granulin' (GRN), and hexanucleotide repeat expansions in 'chromosome 9 open reading frame72' (C9ORF72).

Preliminary data from the study, reported last July, showed that treatment with AL001 resulted in sustained restoration of plasma progranulin levels in all FTD-GRN participants back to normal range and the majority of symptomatic FTD-GRN participants showed a decrease in plasma neurofilament light chain (NfL) levels from baseline.

ALEC closed Friday's (Jul.23, 2021) trading at $32.77, up 3.18%.

5. Biogen Inc. (BIIB)

Biogen will be making several presentations highlighting data on its recently approved drug ADUHELM as well as its broader Alzheimer's disease portfolio and research in the field at the Conference.

ADUHELM received accelerated approval from the FDA last month for the treatment of Alzheimer's. The drug has run into controversy, with critics questioning its approval due to a lack of data to support it.

With a $56,000 yearly list price, ADUHELM is believed to have earned $2 million in sales in its first few weeks. of availability.

BIIB closed Friday's trading at $325.40, down 0.29%.

For comments and feedback contact: editorial@rttnews.com

Follow RTT